Tag: Pentadeca arginate

In late 2023, the U.S. Food and Drug Administration (FDA) classified BPC-157 as a bulk drug presenting significant safety risks, effectively prohibiting its use in compounded medications. For many users, this regulatory action led to a significant question: **What is the new name for BPC 157?**

The U.S. FDA has not approved BPC-157 for human use and placed it in a category restricting its legal compounding, prompting many to ask: **what has replaced BPC-157** for recovery and healing? [1.4.1, 1.4.4] This has shifted focus toward other research peptides.